



26 April 2017  
26 April 2017  
P.U. (A) 130

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017

*POISONS (AMENDMENT OF POISONS LIST) ORDER 2017*

DISIARKAN OLEH/  
*PUBLISHED BY*  
JABATAN PEGUAM NEGARA/  
*ATTORNEY GENERAL'S CHAMBERS*

## AKTA RACUN 1952

## PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2017**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Bencyclane; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bendamustine	-	All preparations”;				

(ii) dengan memasukkan selepas butiran “Celecoxib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ceritinib	-	All preparations”;				

(iii) dengan memasukkan selepas butiran “Crizotinib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Crofelemer	-	-	All preparations”;			

(iv) dengan memasukkan selepas butiran “Dabigatran” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Daclatasvir	-	All preparations”;				

- (v) dengan menggantikan butiran “Dextrophan; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dextrophan; its salts	-	-	All preparations”;			

- (vi) dengan memasukkan selepas butiran “Drotrecogin alfa (Recombinant human activated Protein C)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dulaglutide	-	All preparations”;				

- (vii) dengan memasukkan selepas butiran “Elaterin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Elosulfase	-	All preparations”;				

(viii) dengan memasukkan selepas butiran “Fazadinium bromide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Febuxostat	-	All preparations”;				

(ix) dengan memotong butiran “Febantel” dan butir-butir yang berhubungan dengannya;

(x) dengan memasukkan selepas butiran “Idarubicin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Idelalisib	-	All preparations”;				

- (xi) dengan memasukkan selepas butiran “Lead tetraethyl” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ledipasvir	-	All preparations”;				

- (xii) dengan memasukkan selepas butiran “Nepafenac” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Netupitant	-	All preparations”;				

- (xiii) dengan memasukkan selepas butiran “Nimorazole” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nintedanib	-	All preparations”;				

- (xiv) dengan memotong butiran “Praziquantel” dan butir-butir yang berhubungan dengannya;

(xv) dengan memasukkan selepas butiran “Ruxolitinib” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sacubitril	-	All preparations”;				

(xvi) dengan memasukkan selepas butiran “Secnidazole” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Secukinumab	-	All preparations”;				

(xvii) dalam butiran “Ulipristal”, dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ulipristal	-	-	All preparations”;			

(xviii) dengan memasukkan selepas butiran “Viloxazine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vismodegib	-	All preparations”; dan				

(b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai “**Anthelmintics:**”, dengan memotong butiran “Febantel” dan “Praziquantel”;
- (ii) dalam senarai “**Antidiabetics:**”, dengan memasukkan selepas butiran “Dapagliflozin” butiran “Dulaglutide”;
- (iii) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
  - (A) dengan memasukkan selepas butiran “Belimumab” butiran “Bendamustine”;
  - (B) dengan memasukkan selepas butiran “Carmustine; its salts” butiran “Ceritinib”;
  - (C) dengan memasukkan selepas butiran “Idarubicin” butiran “Idelalisib”;

- (D) dengan memasukkan selepas butiran “Nilotinib” butiran “Nintedanib”;
- (E) dengan memasukkan selepas butiran “Ruxolitinib” butiran “Secukinumab”; dan
- (F) dengan memasukkan selepas butiran “Vinca, alkaloids of, including synthetic preparations” butiran “Vismodegib”;
- (iv) dalam senarai “**Antitussive:**”, dengan menggantikan butiran “Destrophan; its salts” dengan butiran “Dextrophan; its salts”;
- (v) dalam senarai “**Antiviral agents:**”—
  - (A) dengan memasukkan selepas butiran “Clevudine” butiran “Daclatasvir”; dan
  - (B) dengan memasukkan selepas butiran “Lamivudine” butiran “Ledipasvir”;
- (vi) dalam senarai “**Cardio drugs:**”, dengan memasukkan selepas butiran “Quinidine; its salts” butiran “Sacubitril”;
- (vii) dalam senarai “**Uricosuric agents:**”, dengan memasukkan selepas butiran “Colchicine” butiran “Febuxostat”; dan
- (viii) dalam senarai “**Miscellaneous:**”—

- (A) dengan memasukkan selepas butiran “Creosote, obtained from wood” butiran “Crofelemer”;
- (B) dengan memasukkan selepas butiran “Elaterin” butiran “Elosulfase”; dan
- (C) dengan memasukkan selepas butiran “Nedocromil sodium” butiran “Netupitant”.

Dibuat 17 Mac 2017  
[KK(R)608(14); PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) ORDER 2017

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2017**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by inserting after the item “Bencyclane; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Bendamustine	-	All preparations”;					

(ii) by inserting after the item “Celecoxib” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ceritinib	-	All preparations”;				

(iii) by inserting after the item “Crizotinib” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Crofelemer	-	-	All preparations”;			

(iv) by inserting after the item “Dabigatran” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Daclatasvir	-	All preparations”;				

(v) by substituting for the item “Dextrophan; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dextrophan; its salts	-	-	All preparations”;			

(vi) by inserting after the item “Drotrecogin alfa (Recombinant human activated Protein C)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dulaglutide	-	All preparations”;				

(vii) by inserting after the item “Elaterin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Elosulfase	-	All preparations”;				

(viii) by inserting after the item “Fazadinium bromide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Febuxostat	-	All preparations”;				

(ix) by deleting the item “Febantel” and the particulars relating to it;

(x) by inserting after the item “Idarubicin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Idelalisib	-	All preparations”;				

(xi) by inserting after the item “Lead tetraethyl” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ledipasvir	-	All preparations”;				

(xii) by inserting after the item “Nepafenac” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Netupitant	-	All preparations”;				

(xiii) by inserting after the item “Nimorazole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nintedanib	-	All preparations”;				

(xiv) by deleting the item “Praziquantel” and the particulars relating to it;

(xv) by inserting after the item “Ruxolitinib” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sacubitril	-	All preparations”;				

(xvi) by inserting after the item “Secnidazole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Secukinumab	-	All preparations”;				

(xvii) in the item “Ulipristal”, by substituting for the particulars relating to it the following particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ulipristal	-	-	All preparations”;		and	

(xviii) by inserting after the item “Viloxazine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vismodegib	-	All preparations”;			and	

(b) in the Appendix to the Poisons List—

- (i) under the list of “**Anthelmintics:**”, by deleting the items “Febantel” and “Praziquantel”;
- (ii) under the list of “**Antidiabetics:**”, by inserting after the item “Dapagliflozin” the item “Dulaglutide”;
- (iii) under the list of “**Antineoplastic agents and Immunosuppressants:**”—
  - (A) by inserting after the item “Belimumab” the item “Bendamustine”;
  - (B) by inserting after the item “Carmustine; its salts” the item “Ceritinib”;
  - (C) by inserting after the item “Idarubicin” the item “Idelalisib”;
  - (D) by inserting after the item “Nilotinib” the item “Nintedanib”;
  - (E) by inserting after the item “Ruxolitinib” the item “Secukinumab”; and
  - (F) by inserting after the item “Vinca, alkaloids of, including synthetic preparations” the item “Vismodegib”;
- (iv) under the list of “**Antitussive:**”, by substituting for the item “Destrophan; its salts” the item “Dextrophan; its salts”;

- (v) under the list of “**Antiviral agents:**” —
  - (A) by inserting after the item “Clevudine” the item “Daclatasvir”; and
  - (B) by inserting after the item “Lamivudine” the item “Ledipasvir”;
- (vi) under the list of “**Cardio Drugs:**”, by inserting after the item “Quinidine, its salts” the item “Sacubitril”;
- (vii) under the list of “**Uricosuric agents:**”, by inserting after the item “Colchicine” the item “Febuxostat”; and
- (viii) under the list of “**Miscellaneous:**” —
  - (A) by inserting after the item “Creosote, obtained from wood” the item “Crofelemer”;
  - (B) by inserting after the item “Elaterin” the item “Elosulfase”; and
  - (C) by inserting after the item “Nedocromil sodium” the item “Netupitant”.

Made 17 March 2017  
[KK(R)608(14); PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM  
*Minister of Health*